The liver's leak alarm. Alanine aminotransferase (ALT) sits inside hepatocytes, and when those cells are injured the enzyme spills into plasma — which is why an ALT blood draw is the front-line test for liver damage.
ALT is a classic transaminase: a ping-pong transfer of an amino group from alanine onto alpha-ketoglutarate, producing pyruvate and glutamate. The pyridoxal phosphate cofactor shuttles the amino group as pyridoxamine phosphate between the two half-reactions. Because the equilibrium is near unity, ALT runs just as happily backward, synthesizing alanine when pyruvate and glutamate are abundant.
Regulation
Expression rises with protein intake and with cortisol, which induces hepatic transaminases during fasting.
Minute-to-minute flux follows substrate availability: rising pyruvate pushes alanine synthesis in the glucose-alanine cycle.
Vitamin B6 deficiency lowers measured ALT activity — the clinical assay reads cofactor status as much as enzyme mass.
Physiological Role
Anchor of the glucose-alanine cycle: muscle exports nitrogen as alanine, the liver returns it as pyruvate for gluconeogenesis — an ammonia-free nitrogen shuttle.
Couples amino-acid catabolism to the TCA cycle through alpha-ketoglutarate and to urea cycle disposal via glutamate.
Constitutive hepatic expression keeps alanine from accumulating during everyday protein turnover.
Interactions
Partner aspartate aminotransferase shares the alpha-ketoglutarate substrate; the AST/ALT ratio separates alcoholic liver injury from viral and metabolic injury.
The glutamate product links to ammonia fixation and, in brain, to the glutamate transmitter pool — though ALT's role there is metabolic, not synaptic.
Coordinates with urea-cycle enzymes of the liver to keep blood ammonia low.
Clinical Relevance
Serum ALT elevation is the standard marker of hepatocellular injury: viral hepatitis, steatohepatitis, drug injury, ischemia.
Values in the thousands indicate acute necrosis — acetaminophen toxicity or ischemic hepatitis.
Normal ALT in obesity can still hide advanced fibrosis; fatty-liver guidelines no longer treat ALT as the sole gatekeeper.